Extended Data Table 1 Effects of semaglutide versus placebo on 14 hallmark gene sets in individuals with MASH receiving once-daily subcutaneous semaglutide 0.4 mg or placebo for 72 weeks

From: Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis

  1. A gene set enrichment analysis was performed using the hallmark gene set collection of 50 gene sets generated from the Molecular Signatures Database. Model estimates (from a mixed model for repeated measures analysis) for the treatment ratio of semaglutide 0.4 mg/placebo at week 72 for all 4,979 protein biomarkers in the SomaScan assay were included in the analysis. Statistically significant effect of semaglutide 0.4 mg versus placebo was defined as an FDR-adjusted P value (q value) < 0.2. Only gene sets with significant treatment effect of semaglutide 0.4 mg versus placebo are shown. As an example, the top-ranked enriched hallmark gene set was fatty acid metabolism. The table shows that the gene set is downregulated, meaning that genes/proteins in this pathway are expressed less in patients treated with high-dose semaglutide compared to placebo.
  2. aIncluded in the analysis
  3. bSemaglutide 0.4 mg versus placebo.
  4. HIF1A, hypoxia-inducible factor 1-alpha; MASH, metabolic dysfunction-associated steatohepatitis; mTORC1, mammalian target of rapamycin complex 1.
Back to article page